Professor Laurent Rivory

Pro-Vice Chancellor (Strategic Collaborations and Partnerships)

G02 - Jane Foss Russell Building
The University of Sydney

Telephone +61 2 8627 0624
Fax +61 2 8627 8145

Biographical details

Professor Laurent Rivory is the Pro Vice-Chancellor (Strategic Collaborations & Partnerships) in the office of the Deputy Vice Chancellor Research. Professor Rivory’s role has a particular focus on the areas where cross-faculty engagement and external partnerships are integral to the academic enterprise. An important aspect of the role is developing and establishing frameworks and governance arrangements that enable appropriate integration with external partners to increase translation into practice, new capability and impact of the University's research and education output. Professor Rivory will work closely with deputy vice-chancellors and deans to realise the strategic mission of each SEG-endorsed Strategic Priority ARea for Collaboration (SPARC).

Professor Rivory has 20 years experience in research and leadership, which has spanned the higher education, hospital and industry sectors. He is widely recognised for his research in cancer drug pharmacology and has extensive experience in the management of key research programmes in virology, immunology, cancer, RNA therapeutics and diagnostics which were conducted through his appointments at the University of Queensland, the Royal Prince Alfred Hospital, the Université de Bordeaux II and the Fondation Bergonié, and the University of Sydney. Laurent was recruited to Johnson and Johnson in 2002 where he rose to the position of Senior Research Director, Research and Development before returning to the higher education sector to take the role of Director of the Research Strategy Office at the University of New South Wales.

He has also had previous appointments as Clinical Senior Lecturer at the University of Sydney and as head of the Pharmacology Laboratory, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown.

Research interests

Professor Rivory's research interests include cancer drug discovery and development, HCV, innate immunity and RNA interference. He has supervised 8 PhD students to completion, including 4 at the University of Sydney. He is a Graduate of the Australian Institute of Company Directors (AICD).

Associations

  1. Board Member Nominee, Bionic Vision Australia(an ARC Strategic Research Initiative administered by the University of Melbourne) (2010-2014)
  2. Director and Chair, Bionic Vision Technologies (2013-2014)
  3. Chair, Advisory Board, ARC Centre of Excellence in Cognition and Its Disorders (administered by Macquarie University)
  4. GovernanceCommittee Member, Stem Cells Australia (an ARC Strategic Research Initiative administered by the University of Melbourne) (2011-2014)
  5. Committee member, Bellberry Ethics
  6. NHMRC DEvelopment Grant Scheme GRP member
  7. Editor of theJournal of Clinical Oncology (2002-2005)
  8. Editor of the British Journal of Pharmacology (2003-2007)
  9. External Expert Evaluator for the Australian Therapeutics Goods Administration, TGA (1999-2002)
  10. Member of the Pharmaceutical Subcommittee (PSC) of the Australian Drug Evaluation Committee, ADEC (2001-2002)
  11. Author of Draft Discussion Papers for the Australian Drug Evaluation Committee (ADEC)
  12. Reviewer of manuscripts for a number of Cancer, Pharmacology and Nucleic Acid Technology journals as well as a number of competitivegranting schemes such as the NHMRC, Wellcome Trust
  13. Invited speakerships for workshops and international conferences including Meet-The-Professor at ASCO conference
  14. Consultant for several pharmaceutical, scientific and biotechnology companies and entities including ANSTO

Selected grants

2003

  • Interaction of new kinase inhibitor drugs with multi-drug resistance (MDR) transporter proteins; Haber M, Allen J, Rivory L; National Health and Medical Research Council (NHMRC)/Project Grants.

2001

  • The effects of ageing on cancer chemotherapy; Rivory L, Clarke S, McLachlan A; National Health and Medical Research Council (NHMRC)/Project Grants.

2000

  • Overcoming inter-individual variability in cancer chemotherapy; Rivory L; Cancer Council New South Wales/Research Project Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Tanudji, M., Machalek, D., Arndt, G., Rivory, L. (2010). Competition Between siRNA Duplexes: Impact of RNA-Induced Silencing Complex Loading Efficiency and Comparison Between Conventional-21 bp and Dicer-Substrate siRNAs. Oligonucleotides, 20(1), 27-32. [More Information]
  • Moses, J., Goodchild, A., Rivory, L. (2010). Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. RNA, 16(2), 430-441. [More Information]
  • Passioura, T., Gozar, M., Goodchild, A., King, A., Arndt, G., Poidinger, M., Birkett, D., Rivory, L. (2009). Interfering ribonucleic acids that suppress expression of multiple unrelated genes. BMC Biotechnology, 9, 1-11. [More Information]
  • Goodchild, A., Nopper, N., Craddock, A., Law, T., King, A., Fanning, G., Rivory, L., Passioura, T. (2009). Primary Leukocyte Screens for Innate Immune Agonists. Journal of Biomolecular Screening, 14(6), 723-730. [More Information]
  • Goodchild, A., Nopper, N., King, A., Doan, T., Tanudji, M., Arndt, G., Poidinger, M., Rivory, L., Passioura, T. (2009). Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunology, 10, 1-13. [More Information]
  • Gozar, M., Goodchild, A., Passioura, T., King, A., Lai, A., Witherington, C., Rivory, L. (2008). Dz13, a DNAzyme Targeting c-jun, Induces Off-Target Cytotoxicity in Endothelial Cells with Features of Nonapoptotic Programmed Cell Death. Oligonucleotides, 18(3), 257-268. [More Information]
  • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. (2008). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research, 14(3), 817-825. [More Information]
  • Li, K., Rivory, L., Hoskins, J., Sharma, R., Clarke, S. (2007). Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British Journal of Clinical Pharmacology, 63(1), 67-74. [More Information]
  • Goodchild, A., King, A., Gozar, M., Passioura, T., Tucker, C., Rivory, L. (2007). Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Research, 35(13), 4562-4572. [More Information]
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology & Therapeutics, 82(1), 33-40. [More Information]
  • Montaudon, D., Palle, K., Rivory, L., Robert, J., Douat-Casassus, C., Quideau, S., Bjornsti, M., Pourquier, P. (2007). Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505. Journal of Biological Chemistry, 282(19), 14403-14412. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2007). Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. British Journal of Cancer, 97(8), 1071-1076. [More Information]
  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Tobin, P., Beale, P., Noney, L., Liddell, S., Rivory, L., Clarke, S. (2006). A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 57(3), 309-316. [More Information]
  • Li, K., Rivory, L., Hoskins, J., Sharma, R., Clarke, S. (2006). Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British Journal of Clinical Pharmacology, 63(1), 67-74. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2006). Solid-phase extraction (SPE) techniques for sample preparation in clinical and pharmaceutical analysis: A brief overview. Current Pharmaceutical Analysis, 2(2), 95-102. [More Information]
  • Rivory, L., Tucker, C., King, A., Lai, A., Goodchild, A., Witherington, C., Gozar, M., Birkett, D. (2006). The DNAzymes Rs6, Dz13, and DzF Have Potent Biologic Effects Independent of Catalytic Activity. Oligonucleotides, 16(4), 297-312. [More Information]
  • Tobin, P., Clarke, S., Seale, J., Lee, S., Solomon, M., Aulds, S., Crawford, M., Gallagher, J., Eyers, T., Rivory, L. (2006). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. British Journal of Clinical Pharmacology, 62(1), 122-129. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]
  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology & Therapeutics, 77(1), 33-42. [More Information]
  • Tobin, P., Hong, Y., Seale, J., Rivory, L., McLachlan, A. (2005). Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. Journal of Pharmacy and Pharmacology, 57, 39-45. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2005). Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 820(1), 121-130. [More Information]
  • Le Couteur, D., Fraser, R., Hilmer, S., Rivory, L., McLean, A. (2005). The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clinical Pharmacokinetics, 44(2), 187-200. [More Information]
  • Pajic, M., Bebawy, M., Hoskins, J., Roufogalis, B., Rivory, L. (2004). Effect Of Short-Term Morphine Exposure On P-Glycoprotein Expression And Activity In Cancer Cell Lines. Oncology Reports, 11(5), 1091-1095.
  • Baker, S., Van Schaik, R., Rivory, L., Ten Tije, A., Dinh, K., Graveland, W., Schenk, P., Charles, J., Clarke, S., Carducci, M., Sparreboom, A., et al (2004). Factors Affecting Cytochrome P-450 3A Activity In Cancer Patients. Clinical Cancer Research, 10(12), 8341-8350.
  • Tobin, P., Rivory, L., Clarke, S. (2004). Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). Pharmacology and Therapeutics, 76(5), 505-506.
  • Blair, E., Rivory, L., Clarke, S., McLachlan, A. (2004). Population Pharmacokinetics Of Raltitrexed In Patients With Advanced Solid Tumours. British Journal of Clinical Pharmacology, 57(4), 416-426.
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.
  • Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
  • Le Couteur, D., Yin, Z., McLean, A., Rivory, L. (2004). Wash-In Methodology And Modeling To Determine Hepatocellular D-Glucose Transport In The Perfused Rat Liver. Japanese journal of physiology, 54(4), 421-429.
  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.
  • Sangalli, M., McLean, A., Peek, M., Rivory, L., Le Couteur, D. (2003). Carbon monoxide disposition and permeability-surface area product in the foetal circulation of the perfused term human placenta. Placenta, 24(1), 8-11.
  • Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology, 4(4), 224-232.
  • Li, K., Clarke, S., Rivory, L. (2003). Quantitation of plasma thymidine by high-performance liquid chromatography - atmospheric pressure chemical ionization mass spectromentry and its application to pharmocodynamic studies in cancer patients. Analytica Chimica Acta, 486(1), 51-61.
  • Tobin, P., Dodds, H., Clarke, S., Schnitzler, M., Rivory, L. (2003). The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncology Reports, 10(6), 1977-1979.
  • Shenfield, G., Le Couteur, D., Rivory, L. (2002). Clinical pharmacology. Medical Journal of Australia, , 9-9.
  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280.
  • Boyer, M., Rivory, L., Clarke, S. (2002). Pemetrexed: single-agent and combination phase 1 study overview. Seminars in Oncology, 29(6 - Supplement 18), 18-23.
  • Dodds, H., Tobin, P., Stewart, C., Cheshire, P., Hanna, S., Houghton, P., Rivory, L. (2002). The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. Journal of Pharmacology and Experimental Therapeutics, 303(2), 649-655.
  • Cho, S., McLean, A., Rivory, L., Gatenby, P., Le Couteur, D., Hardman,, D. (2001). Carbon monoxide wash-in method to determine gas transfer in vascular beds: application to rat hindlimb. American Journal of Physiology: Heart and Circulatory Physiology, 280.
  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.
  • Clarke, S., Bishop, J., Dodds, H., Rivory, L., Ong,, S. (2001). Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti-Cancer Drugs, 12, 619-625.
  • Clarke, S., Beale, P., Rivory, L. (2000). Clinical and preclinical pharmacokinetics of raltitrexed. Clinical Pharmacokinetics, 39, 429-443.
  • Rivory, L., Qin, H., Clarke, S., Eris, J., Duggin, G., Ray, E., Trent, R., Bishop, J. (2000). Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. European Journal of Clinical Pharmacology, 56, 395-398.
  • Yang, M., McLean, A., Rivory, L., Le Couteur, D. (2000). Hepatic Disposition of Neurotoxins and Pesticides. Pharmacology and Toxicology, 87(6), 286-291.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

Conferences

  • Tobin, P., Seale, P., Lee, S., Solomon, M., Fields, S., Rivory, L., Clarke, S. (2005). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.

Patents

  • Rivory, L., Birkett, D. (2007). Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells. Patent No. WO/2007/000676.
  • Rivory, L., Arndt, G., Poidinger, M., Passioura, T., Birkett, D. (2007). Multi-targeting interfering RNAs and methods of their use and design. Patent No. WO/2007/056826.
  • Rivory, L., Arndt, G., Poidinger, M., Passioura, T., Birkett, D. (2007). Multi-targeting interfering RNAs having two active strands and methods for their design and use. Patent No. WO/2007/056829.
  • Arndt, G., Nakada, M., Lomas, M., Rivory, L., Tang, Y., Yan, L. (2006). Emmprin antagonists and uses thereof. Patent No. WO/2006/039343.

2010

  • Tanudji, M., Machalek, D., Arndt, G., Rivory, L. (2010). Competition Between siRNA Duplexes: Impact of RNA-Induced Silencing Complex Loading Efficiency and Comparison Between Conventional-21 bp and Dicer-Substrate siRNAs. Oligonucleotides, 20(1), 27-32. [More Information]
  • Moses, J., Goodchild, A., Rivory, L. (2010). Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting. RNA, 16(2), 430-441. [More Information]

2009

  • Passioura, T., Gozar, M., Goodchild, A., King, A., Arndt, G., Poidinger, M., Birkett, D., Rivory, L. (2009). Interfering ribonucleic acids that suppress expression of multiple unrelated genes. BMC Biotechnology, 9, 1-11. [More Information]
  • Goodchild, A., Nopper, N., Craddock, A., Law, T., King, A., Fanning, G., Rivory, L., Passioura, T. (2009). Primary Leukocyte Screens for Innate Immune Agonists. Journal of Biomolecular Screening, 14(6), 723-730. [More Information]
  • Goodchild, A., Nopper, N., King, A., Doan, T., Tanudji, M., Arndt, G., Poidinger, M., Rivory, L., Passioura, T. (2009). Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunology, 10, 1-13. [More Information]

2008

  • Gozar, M., Goodchild, A., Passioura, T., King, A., Lai, A., Witherington, C., Rivory, L. (2008). Dz13, a DNAzyme Targeting c-jun, Induces Off-Target Cytotoxicity in Endothelial Cells with Features of Nonapoptotic Programmed Cell Death. Oligonucleotides, 18(3), 257-268. [More Information]
  • Sharma, R., Hoskins, J., Rivory, L., Zucknick, M., London, R., Liddle, C., Clarke, S. (2008). Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients. Clinical Cancer Research, 14(3), 817-825. [More Information]

2007

  • Li, K., Rivory, L., Hoskins, J., Sharma, R., Clarke, S. (2007). Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British Journal of Clinical Pharmacology, 63(1), 67-74. [More Information]
  • Goodchild, A., King, A., Gozar, M., Passioura, T., Tucker, C., Rivory, L. (2007). Cytotoxic G-rich oligodeoxynucleotides: putative protein targets and required sequence motif. Nucleic Acids Research, 35(13), 4562-4572. [More Information]
  • Rivory, L., Birkett, D. (2007). Guanosine-rich oligonucleotides as agents for inducing cell death in eukaryotic cells. Patent No. WO/2007/000676.
  • Gurney, H., Wong, M., Balleine, R., Rivory, L., McLachlan, A., Hoskins, J., Wilcken, N., Clarke, C., Mann, G., Collins, M., et al (2007). Imatinib Disposition and ABCB1 (MDR1, P-Glycoprotein) Genotype. Clinical Pharmacology & Therapeutics, 82(1), 33-40. [More Information]
  • Montaudon, D., Palle, K., Rivory, L., Robert, J., Douat-Casassus, C., Quideau, S., Bjornsti, M., Pourquier, P. (2007). Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505. Journal of Biological Chemistry, 282(19), 14403-14412. [More Information]
  • Rivory, L., Arndt, G., Poidinger, M., Passioura, T., Birkett, D. (2007). Multi-targeting interfering RNAs and methods of their use and design. Patent No. WO/2007/056826.
  • Rivory, L., Arndt, G., Poidinger, M., Passioura, T., Birkett, D. (2007). Multi-targeting interfering RNAs having two active strands and methods for their design and use. Patent No. WO/2007/056829.
  • Li, K., Rivory, L., Clarke, S. (2007). Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. British Journal of Cancer, 97(8), 1071-1076. [More Information]

2006

  • Sharma, R., Rivory, L., Beale, P., Ong, S., Horvath, L., Clarke, S. (2006). A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British Journal of Cancer, 94(7), 964-968. [More Information]
  • Tobin, P., Beale, P., Noney, L., Liddell, S., Rivory, L., Clarke, S. (2006). A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 57(3), 309-316. [More Information]
  • Li, K., Rivory, L., Hoskins, J., Sharma, R., Clarke, S. (2006). Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British Journal of Clinical Pharmacology, 63(1), 67-74. [More Information]
  • Arndt, G., Nakada, M., Lomas, M., Rivory, L., Tang, Y., Yan, L. (2006). Emmprin antagonists and uses thereof. Patent No. WO/2006/039343.
  • Charles (nee Slaviero), K., Rivory, L., Stockler, M., Beale, P., Beith, J., Boyer, M., Clarke, S. (2006). Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical Pharmacokinetics, 45(6), 611-622. [More Information]
  • WONG, M., Balleine, R., Blair, E., McLachlan, A., Ackland, S., Garg, M., Evans, S., Farlow, D., Collins, M., Rivory, L., Hoskins, J., Mann, G., Clarke, C., Gurney, H. (2006). Predictors of Vinorelbine Pharmacokinetics and Pharmacodynamics in Patients With Cancer. Journal of Clinical Oncology, 24(16), 2448-2455. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2006). Solid-phase extraction (SPE) techniques for sample preparation in clinical and pharmaceutical analysis: A brief overview. Current Pharmaceutical Analysis, 2(2), 95-102. [More Information]
  • Rivory, L., Tucker, C., King, A., Lai, A., Goodchild, A., Witherington, C., Gozar, M., Birkett, D. (2006). The DNAzymes Rs6, Dz13, and DzF Have Potent Biologic Effects Independent of Catalytic Activity. Oligonucleotides, 16(4), 297-312. [More Information]
  • Tobin, P., Clarke, S., Seale, J., Lee, S., Solomon, M., Aulds, S., Crawford, M., Gallagher, J., Eyers, T., Rivory, L. (2006). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. British Journal of Clinical Pharmacology, 62(1), 122-129. [More Information]
  • Charles (nee Slaviero), K., Rivory, L., Brown, S., Liddle, C., Clarke, S., Robertson, G. (2006). Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical Cancer Research, 12(24), 7492-7497. [More Information]

2005

  • Wong, M., Evans, S., Rivory, L., Hoskins, J., Mann, G., Farlow, D., Clarke, C., Balleine, R., Gurney, H. (2005). Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clinical Pharmacology & Therapeutics, 77(1), 33-42. [More Information]
  • Tobin, P., Hong, Y., Seale, J., Rivory, L., McLachlan, A. (2005). Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver. Journal of Pharmacy and Pharmacology, 57, 39-45. [More Information]
  • Li, K., Rivory, L., Clarke, S. (2005). Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 820(1), 121-130. [More Information]
  • Le Couteur, D., Fraser, R., Hilmer, S., Rivory, L., McLean, A. (2005). The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance. Clinical Pharmacokinetics, 44(2), 187-200. [More Information]
  • Tobin, P., Seale, P., Lee, S., Solomon, M., Fields, S., Rivory, L., Clarke, S. (2005). The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. 2005 American Society of Clinical Oncology (ASCO) Annual Meeting, United States: American Society of Clinical Oncology.

2004

  • Pajic, M., Bebawy, M., Hoskins, J., Roufogalis, B., Rivory, L. (2004). Effect Of Short-Term Morphine Exposure On P-Glycoprotein Expression And Activity In Cancer Cell Lines. Oncology Reports, 11(5), 1091-1095.
  • Baker, S., Van Schaik, R., Rivory, L., Ten Tije, A., Dinh, K., Graveland, W., Schenk, P., Charles, J., Clarke, S., Carducci, M., Sparreboom, A., et al (2004). Factors Affecting Cytochrome P-450 3A Activity In Cancer Patients. Clinical Cancer Research, 10(12), 8341-8350.
  • Tobin, P., Rivory, L., Clarke, S. (2004). Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-11). Pharmacology and Therapeutics, 76(5), 505-506.
  • Blair, E., Rivory, L., Clarke, S., McLachlan, A. (2004). Population Pharmacokinetics Of Raltitrexed In Patients With Advanced Solid Tumours. British Journal of Clinical Pharmacology, 57(4), 416-426.
  • Charles (nee Slaviero), K., Clarke, S., McLachlan, A., Blair, E., Rivory, L. (2004). Population Pharmacokinetics Of Weekly Docetaxel In Patients With Advanced Cancer. British Journal of Clinical Pharmacology, 57(1), 44-53.
  • Zhang, M., Boyer, M., Rivory, L., Hong, A., Clarke, S., Stevens, G., Fife, K. (2004). Radiosensitization Of Vinorelbine And Gemcitabine In Nci-H460 Non-Small-Cell Lung Cancer Cells. International Journal of Radiation: Oncology - Biology - Physics, 58(2), 353-360. [More Information]
  • Le Couteur, D., Yin, Z., McLean, A., Rivory, L. (2004). Wash-In Methodology And Modeling To Determine Hepatocellular D-Glucose Transport In The Perfused Rat Liver. Japanese journal of physiology, 54(4), 421-429.

2003

  • Charles (nee Slaviero), K., Read, J., Clarke, S., Rivory, L. (2003). Baseline Nutritional Assessment in Advanced Cancer Patients Receiving Palliative Chemotherapy. Nutrition and Cancer: an international journal, 46(2), 148-157.
  • Sangalli, M., McLean, A., Peek, M., Rivory, L., Le Couteur, D. (2003). Carbon monoxide disposition and permeability-surface area product in the foetal circulation of the perfused term human placenta. Placenta, 24(1), 8-11.
  • Charles (nee Slaviero), K., Clarke, S., Rivory, L. (2003). Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncology, 4(4), 224-232.
  • Li, K., Clarke, S., Rivory, L. (2003). Quantitation of plasma thymidine by high-performance liquid chromatography - atmospheric pressure chemical ionization mass spectromentry and its application to pharmocodynamic studies in cancer patients. Analytica Chimica Acta, 486(1), 51-61.
  • Tobin, P., Dodds, H., Clarke, S., Schnitzler, M., Rivory, L. (2003). The relative contributions of carboxylesterase and beta-glucuronidase in the formation of SN-38 in human colorectal tumours. Oncology Reports, 10(6), 1977-1979.

2002

  • Shenfield, G., Le Couteur, D., Rivory, L. (2002). Clinical pharmacology. Medical Journal of Australia, , 9-9.
  • Rivory, L., Charles (nee Slaviero), K., Clarke, S. (2002). Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. British Journal of Cancer, 87(3), 277-280.
  • Boyer, M., Rivory, L., Clarke, S. (2002). Pemetrexed: single-agent and combination phase 1 study overview. Seminars in Oncology, 29(6 - Supplement 18), 18-23.
  • Dodds, H., Tobin, P., Stewart, C., Cheshire, P., Hanna, S., Houghton, P., Rivory, L. (2002). The importance of tumor glucuronidase in the activation of irinotecan in a mouse xenograft model. Journal of Pharmacology and Experimental Therapeutics, 303(2), 649-655.

2001

  • Cho, S., McLean, A., Rivory, L., Gatenby, P., Le Couteur, D., Hardman,, D. (2001). Carbon monoxide wash-in method to determine gas transfer in vascular beds: application to rat hindlimb. American Journal of Physiology: Heart and Circulatory Physiology, 280.
  • Rivory, L., Clarke, S., Boyer, M., Bishop, J. (2001). Highly sensitive analysis of the antifolate pemetrexed sodium, a new cancer agent, in human plasma and urine by high-performance liquid chromatography. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences, 765, 135-140.
  • Rivory, L., Charles (nee Slaviero), K., Hoskins, J., Clarke, S. (2001). The erythromycin breath test for the prediction of drug clearance. Clinical Pharmacokinetics, 40, 151-158.
  • Clarke, S., Bishop, J., Dodds, H., Rivory, L., Ong,, S. (2001). Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anti-Cancer Drugs, 12, 619-625.

2000

  • Clarke, S., Beale, P., Rivory, L. (2000). Clinical and preclinical pharmacokinetics of raltitrexed. Clinical Pharmacokinetics, 39, 429-443.
  • Rivory, L., Qin, H., Clarke, S., Eris, J., Duggin, G., Ray, E., Trent, R., Bishop, J. (2000). Frequency of cytochrome P450 3A4 variant genotype in transplant population and lack of association with cyclosporin clearance. European Journal of Clinical Pharmacology, 56, 395-398.
  • Yang, M., McLean, A., Rivory, L., Le Couteur, D. (2000). Hepatic Disposition of Neurotoxins and Pesticides. Pharmacology and Toxicology, 87(6), 286-291.
  • Rivory, L., Charles (nee Slaviero), K., Seale, J., Hoskins, J., Boyer, M., Beale, P., Millward, M., Bishop, J., Clarke, S. (2000). Optimizing the erythromycin breath test for use in cancer patients. Clinical Cancer Research, 6, 3480-3485.

To update your profile click here. For support on your academic profile contact .